Advertisement

Topics

FRAME: Romosozumab reduces new vertebral fractures in postmenopausal women with osteoporosis

07:30 EDT 22 Sep 2016 | Healio

In postmenopausal women with osteoporosis, the monoclonal antibody romosozumab was associated with a lower risk for new vertebral fractures vs. placebo at both 12 and 24 months, according to study data presented at the American Society for Bone and Mineral Research annual meeting and simultaneously published online in The New England Journal of Medicine.In a randomized, double blind, placebo-controlled, parallel-group trial, researchers found that patients assigned romosozumab (Amgen/UCB Pharma) also showed improvements in bone mass, with sustained benefits upon the transition to denosumab (Prolia, Amgen) after 12 months.

Original Article: FRAME: Romosozumab reduces new vertebral fractures in postmenopausal women with osteoporosis

NEXT ARTICLE

More From BioPortfolio on "FRAME: Romosozumab reduces new vertebral fractures in postmenopausal women with osteoporosis"

Quick Search
Advertisement
 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...